Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MC4R | P32245 | 7/20 | 0.44 |
| ▸ | MC5R | P33032 | 1/20 | 0.44 |
| ▸ | MC3R | P41968 | 1/20 | 0.44 |
| ▸ | MC1R | Q01726 | 1/20 | 0.44 |
| ▸ | CCKBR | P32239 | 2/20 | 0.40 |
| ▸ | MEN1 | O00255 | 2/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.40 |
| ▸ | CALCRL | Q16602 | 1/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.37 |
| ▸ | GHSR | Q92847 | 2/20 | 0.36 |
| ▸ | F2 | P00734 | 1/20 | 0.35 |
| ▸ | POLB | P06746 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | CCR1 | P32246 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL181669 | 1.00 | MC4R (0.44) | MC4RMC5RMC3RMC1RCCKBR | |
| SCHEMBL29160493 | 1.00 | MC4R (0.44) | MC4RMC5RMC3RMC1RCCKBR | |
| SCHEMBL13185979 | 1.00 | MC4R (0.44) | MC4RMC5RMC3RMC1RCCKBR | |
| SCHEMBL30778907 | 1.00 | MC4R (0.44) | MC4RMC5RMC3RMC1RCCKBR | |
| SCHEMBL30778916 | 1.00 | MC4R (0.44) | MC4RMC5RMC3RMC1RCCKBR | |
| SCHEMBL15640877 | 1.00 | MC4R (0.44) | MC4RMC5RMC3RMC1RCCKBR | |
| Hydrochloric Acid SCHEMBL29160491 | 0.99 | MC4R (0.43) | MC4RMC5RMC3RMC1RCCKBR | |
| Hydrochloric Acid SCHEMBL29160492 | 0.99 | MC4R (0.43) | MC4RMC5RMC3RMC1RCCKBR | |
| Hydrochloric Acid SCHEMBL29160494 | 0.99 | MC4R (0.43) | MC4RMC5RMC3RMC1RCCKBR | |
| Sulfuric Acid SCHEMBL29160497 | 0.97 | MC4R (0.42) | MC4RMC5RMC3RMC1RCCKBR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260146036-A1 | CRYSTALLINE FORMS | RAQUALIA PHARMA INC. (JP) | 2026-05-28 | — | — | US | claimed |
| EP-4377309-B1 | CRYSTALLINE FORMS | RAQUALIA PHARMA INC (JP) | 2026-05-20 | — | — | EP | claimed |
| US-20240351998-A1 | CRYSTALLINE FORMS | RAQUALIA PHARMA INC. (JP) | 2024-10-24 | — | — | US | claimed |
| EP-4377309-A1 | CRYSTALLINE FORMS | RaQualia Pharma Inc. (JP) | 2024-06-05 | — | — | EP | claimed |
| CN-117616022-A | Crystalline forms | 拉夸里亚创药株式会社 | 2024-02-27 | — | — | CN | claimed |
| WO-2023008585-A1 | CRYSTALLINE FORMS | RAQUALIA PHARMA INC. (JP) | 2023-02-02 | — | — | WO | claimed |
| EP-2401268-B1 | OXYINDOLE DERIVATIVES WITH MOTILIN RECEPTOR AGONISTIC ACTIVITY | RAQUALIA PHARMA INC (JP) | 2015-07-29 | — | — | EP | claimed |
| US-8697877-B2 | Oxyindole derivatives with motilin receptor agonistic activity | RAQUALIA PHARMA INC. (JP) | 2014-04-15 | — | — | US | claimed |
| EP-2401268-A1 | OXYINDOLE DERIVATIVES WITH MOTILIN RECEPTOR AGONISTIC ACTIVITY | RaQualia Pharma Inc (JP) | 2012-01-04 | — | — | EP | claimed |
| US-20110312933-A1 | OXYINDOLE DERIVATIVES WITH MOTILIN RECEPTOR AGONISTIC ACTIVITY | RAQUALIA PHARMA INC. (JP) | 2011-12-22 | — | — | US | claimed |
| WO-2010098145-A1 | OXYINDOLE DERIVATIVES WITH MOTILIN RECEPTOR AGONISTIC ACTIVITY | RAQUALIA PHARMA INC. (JP) | 2010-09-02 | — | — | WO | claimed |
| US-20260146036-A1 | CRYSTALLINE FORMS | RAQUALIA PHARMA INC. (JP) | 2026-05-28 | — | — | US | disclosed |
| EP-4377309-B1 | CRYSTALLINE FORMS | RAQUALIA PHARMA INC (JP) | 2026-05-20 | — | — | EP | disclosed |
| US-12552776-B2 | Crystalline forms | RAQUALIA PHARMA INC. (JP) | 2026-02-17 | — | — | US | disclosed |
| US-20240351998-A1 | CRYSTALLINE FORMS | RAQUALIA PHARMA INC. (JP) | 2024-10-24 | — | — | US | disclosed |
| EP-2401268-B1 | OXYINDOLE DERIVATIVES WITH MOTILIN RECEPTOR AGONISTIC ACTIVITY | RAQUALIA PHARMA INC (JP) | 2015-07-29 | — | — | EP | disclosed |
| US-8697877-B2 | Oxyindole derivatives with motilin receptor agonistic activity | RAQUALIA PHARMA INC. (JP) | 2014-04-15 | — | — | US | disclosed |
| EP-2401268-A1 | OXYINDOLE DERIVATIVES WITH MOTILIN RECEPTOR AGONISTIC ACTIVITY | RaQualia Pharma Inc (JP) | 2012-01-04 | — | — | EP | disclosed |
| US-20110312933-A1 | OXYINDOLE DERIVATIVES WITH MOTILIN RECEPTOR AGONISTIC ACTIVITY | RAQUALIA PHARMA INC. (JP) | 2011-12-22 | — | — | US | disclosed |
| WO-2010098145-A1 | OXYINDOLE DERIVATIVES WITH MOTILIN RECEPTOR AGONISTIC ACTIVITY | RAQUALIA PHARMA INC. (JP) | 2010-09-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12552776-B2 | Crystalline forms | MLNR, SIGMAR1, PROKR1 | MC4R 188/4885MC5R 351/4885MC3R 111/4885 |
| US-20110312933-A1 | OXYINDOLE DERIVATIVES WITH MOTILIN RECEPTOR AGONISTIC ACTIVITY | GPR68, GPR88, GPR52 | MC4R 16/4885MC5R 15/4885MC3R 24/4885 |
| US-20260146036-A1 | CRYSTALLINE FORMS | PRKCD, CCT8, CRYZ | MC4R 3906/4885MC5R 4465/4885MC3R 4383/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.